Bio-Gate AG

As of December 31, 2025, Bio-Gate AG carries a market capitalization of 8.00M, placing it among publicly traded companies globally. Its enterprise value stands at 7.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio-Gate AG's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Bio-Gate AG has 2.04M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Bio-Gate AG maintains a current ratio of 2.46, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on July 27, 2026, Bio-Gate AG's stock has declined approximately 24.73% over the past 52 weeks. The 50-day moving average sits at 0.63, while the 200-day moving average is 0.71.

As of December 31, 2025, Bio-Gate AG holds 704,933.50 in cash and equivalents against 52,535.98 in total debt, resulting in a net debt position of -652,397.52. Total book value stands at 1.53M, with working capital of 1.66M providing operational flexibility.

Bio-Gate AG's most recent stock split took place on July 28, 2026 with a 5:1 split ratio.